Phase I study using BK-UM against HB-EGF [heparin binding EGF-like growth factor] for patients with advanced or recurrent ovarian cancer
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs CRM 197 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; First in man
- 07 May 2008 New trial record.